Effect of candesartan on cause-specific mortality in heart failure patients: The candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program (vol 110, pg 2180, 2004)

被引：0
|
作者：
Solomon
机构：
来源：
CIRCULATION | 2005年 / 111卷 / 03期
关键词：
D O I：
10.1161/01.CIR.0000155486.26868.C9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：378 / 378
页数：1
相关论文
共 50 条
  • [31] Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity programme
    Cohen-Solal, Alain
    McMurray, John J. V.
    Swedberg, Karl
    Pfeffer, Marc A.
    Puu, Margareta
    Solomon, Scott D.
    Michelson, Eric L.
    Yusuf, Salim
    Granger, Christopher B.
    EUROPEAN HEART JOURNAL, 2008, 29 (24) : 3022 - 3028
  • [32] Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure The CHARM Programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity)
    Wong, Chih M.
    Hawkins, Nathaniel M.
    Jhund, Pardeep S.
    MacDonald, Michael R.
    Solomon, Scott D.
    Granger, Christopher B.
    Yusuf, Salim
    Pfeffer, Marc A.
    Swedberg, Karl
    Petrie, Mark C.
    McMurray, John J. V.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (20) : 1845 - 1854
  • [33] Comparison of the risk associated with diabetes mellitus in patients with preserved and low ejection fraction heart failure: An analysis of the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program
    MacDonald, Michael R.
    Varyani, Fumi
    Carlsson, Jonas
    Petrie, Mark
    Ostergren, Jan
    Michelson, Eric L.
    Solomon, Scott D.
    Granger, Christopher B.
    Swedberg, Karl
    Pfeffer, Marc A.
    Yusuf, Salim
    McMurray, John J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 61A - 61A
  • [34] Effects of candesartan on mortality and morbidity in patients with chronic heart failure:: the CHARM-Overall programme
    Pfeffer, MA
    Swedberg, K
    Granger, CB
    Held, P
    McMurray, JJV
    Michelson, EL
    Olofsson, B
    Östergren, J
    Yusuf, S
    LANCET, 2003, 362 (9386): : 759 - 766
  • [35] Kardioprotektion durch Candesartan bei HerzinsuffizienzCHARM-overall-Teilauswertung (Candesartan in heart failure assessment of reduction in mortality and morbidity)
    C. Tschöpe
    H. P. Schultheiss
    Der Internist, 2006, 47 : 1084 - 1086
  • [36] Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme (vol 362, pg 759, 2003)
    Pfeffer, M. A.
    Swedberg, K.
    Granger, C. B.
    LANCET, 2009, 374 (9703): : 1744 - 1744
  • [37] Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program
    Meredith, Peter A.
    Ostergren, Jan
    Anand, Inder
    Puu, Margareta
    Solomon, Scott D.
    Michelson, Eric L.
    Olofsson, Bertil
    Granger, Christopher B.
    Yusuf, Salim
    Swedberg, Karl
    Pfeffer, Marc A.
    McMurray, John J. V.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (24) : 2000 - 2007
  • [38] Reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: Results of the CHARM low
    Young, JB
    Swedberg, K
    Dunlap, ME
    Pfeffer, MA
    Probstfield, JL
    Granger, CB
    McKelvey, RS
    McMurray, MJV
    Michaelson, EL
    Olofsson, B
    Ostergren, J
    Yusuf, S
    JOURNAL OF CARDIAC FAILURE, 2004, 10 (04) : S76 - S76
  • [39] Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial
    Weir, R. A. P.
    Mcmurray, J. J. V.
    Granger, C. B.
    Puu, M.
    Ostergren, J.
    Yusuf, S.
    Swedberg, K.
    Pfeffer, M. A.
    EUROPEAN HEART JOURNAL, 2006, 27 : 331 - 331
  • [40] Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the candesartan in heart failure:: Assessment of reduction in mortality and morbidity (CHARM)-Added trial
    McMurray, JJV
    Young, JB
    Dunlap, ME
    Granger, CB
    Hainer, J
    Michelson, EL
    Earle, S
    Olofsson, B
    Östergren, J
    Yusuf, S
    Swedberg, K
    Pfeffer, MA
    AMERICAN HEART JOURNAL, 2006, 151 (05) : 985 - 991
12345